Daijia recently completed a US$10.0 million Series A-2 fundraising round to support working capital, to enable the Company to push forwards with its plans to broaden its sales channels, and to fund certain R&D expenses.
About Daijia
Shanghai Daijia Medical Information Systems Ltd., is a Shanghai based healthcare IT company that engages in research, development, manufacturing, sales, system integration and maintenance services for Data and Imaging solutions, and other healthcare IT solutions.
Buchang held its 2016 Annual Shareholder Meeting in May 2017, where it approved the payment of its FY2016 dividend. The Company will distribute a total cash dividend of RMB 1.1 billion, or RMB 16.14 for every 10 shares held (before tax). The dividend is expected to be distributed in July 2017.
About Buchang
Buchang Pharmaceuticals is one of the leading traditional Chinese medicine (TCM) companies in China. Buchang was founded in 1993 by Mr. Zhao Buchang and his eldest son, Mr. Zhao Tao. Starting as a small TCM drug manufacturer, Buchang has evolved into a sales and marketing powerhouse. The Company has the most extensive sales network amongst its peers in China, covering over 15,000 hospitals and 150,000 drug stores. The Company’s product portfolio consists of in-house developed products, as well as products that it acquired and turned into blockbusters. Buchang’s brand name is widely recognized by physicians and patients throughout China.
Dongcheng, a pharmaceutical company listed on the A-share market (SZSE:002675), signed an agreement to acquire 100% of the outstanding shares of AMS in May 2017. The transaction values AMS at a valuation of RMB1.6 billion, which is equivalent to a FY2016 P/E multiple of 24.4x.
According to the agreement, SKR expects to receive a cash payment for 50% of its shareholding on completion of the transaction based on a valuation of RMB1.6 billion, and an additional cash payment for the remaining 50% shareholding at the fair market valuation of AMS based on FY2019’s audited financial statements.
About AMS
Advanced Medical Systems Limited provides radiopharmaceuticals to hospitals and imaging centres for use in Positron Emission Tomography (“PET”) scanners and Positron Emission Tomography / Computed Tomography (“PET/CT”) scanners. The Company is the #1 player in China in the positron radiopharmaceutical industry and one of only two companies licensed to produce and sell Fluorodeoxy- glucose (F18-FDG), which is used in PET/CT scanners. AMS also distributes cyclotrons and provides maintenance services for nuclear medicine equipment.